Positive Ph I data for NXN-188

USA-based NeurAxon has reported positive Phase I clinical safety and pharmacokinetic profile data on NXN-188. The agent is a first-in-class, dual-action, small-molecule that is being developed for the treatment of acute migraine and which incorporates both 5-HT agonism and neuronal nitric oxide synthase inhibition, a validated mode of migraine therapy.

The Phase I randomized, double-blind, placebo-controlled, dose-escalation study enrolled healthy volunteers. Nine dosage levels were evaluated with subjects receiving single oral doses of either NXN-188 or placebo. The agent was well tolerated, with no drug-related adverse events reported, NeurAxon noted.